Veritus Research
Melbourne, Victoria, Australia
NCT Number: NCT07390747
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants
This study is active but is not currently recruiting participants.
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Melbourne, Victoria, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Main inclusion criteria
Main exclusion Criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Single dose SHR-2173 injection or matching placebo given subcutaneously
Time frame: Day 71
Maximum observed plasma concentration (Cmax)
Time frame: Day 71
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC₀-t)
Time frame: Day 71
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC₀-inf)
Time frame: Day 71
Time to reach maximum observed plasma concentration (Tmax)
Time frame: Day 71
Terminal elimination half-life (t½)
Time frame: Day 71
Incidence and onset time of anti-drug antibody (ADA)
Time frame: Day 71
Number of participants with Adverse events and Serious adverse events
Atridia Pty Ltd.
Industry
A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Subcutaneous Administration of SHR-2173 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07493460
Healthy Adults, Immunology
St Louis, Missouri, United States
View Trial DetailsNCT03213275
Immunology, Microbiome
Vienna, Austria
View Trial DetailsNCT04974892
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
London, United Kingdom
View Trial DetailsNCT06795945
Immunology
Tampa, Florida, United States
View Trial Details